

Condensed Consolidated Statements of Earnings (Unaudited)

Dollars in millions, except per share data

	Three months ended		Nine months ended	
	03/31/2025	03/31/2024	3/31/2025	3/31/2024
Net sales	\$ 1,668	\$ 1,814	\$ 5,116	\$ 5,190
Cost of products sold	924	1,048	2,827	3,026
Gross profit	744	766	2,289	2,164
Selling and administrative expenses	267	301	828	899
Advertising costs	207	215	599	566
Research and development costs	27	32	89	93
Loss on divestiture	—	240	118	240
Pension settlement charge	—	—	—	171
Interest expense	23	22	66	69
Other (income) expense, net	(34)	(2)	(79)	3
Earnings (losses) before income taxes	254	(42)	668	123
Income tax expense	63	8	180	52
Net earnings (losses)	191	(50)	488	71
Less: Net earnings attributable to noncontrolling interests	5	1	10	7
Net earnings (losses) attributable to Clorox	\$ 186	\$ (51)	\$ 478	\$ 64
Net earnings (losses) per share attributable to Clorox				
Basic net earnings (losses) per share	\$ 1.51	\$ (0.41)	\$ 3.87	\$ 0.52
Diluted net earnings (losses) per share	\$ 1.50	\$ (0.41)	\$ 3.84	\$ 0.52
Weighted average shares outstanding (in thousands)				
Basic	123,367	124,249	123,643	124,133
Diluted	124,066	124,249	124,468	124,721

Reportable Segment Information

(Unaudited)

Dollars in millions

	Net sales			Net sales		
	Three months ended			Nine months ended		
	3/31/2025	3/31/2024	% Change ⁽¹⁾	3/31/2025	3/31/2024	% Change ⁽¹⁾
Health and Wellness	\$ 630	\$ 609	3 %	\$ 1,956	\$ 1,833	7 %
Household	469	526	(11)	1,362	1,353	1
Lifestyle	306	315	(3)	964	947	2
International	263	310	(15)	796	891	(11)
Reportable segment total	1,668	1,760		5,078	5,024	
Corporate and Other ⁽²⁾	—	54	(100)	38	166	(77)
Total	\$ 1,668	\$ 1,814	(8)%	\$ 5,116	\$ 5,190	(1)%

	Segment adjusted EBIT			Segment adjusted EBIT		
	Three months ended			Nine months ended		
	3/31/2025	3/31/2024	% Change ⁽¹⁾	3/31/2025	3/31/2024	% Change ⁽¹⁾
Health and Wellness	\$ 169	\$ 154	10 %	\$ 597	\$ 517	15 %
Household	61	74	(18)%	169	162	4
Lifestyle	60	64	(6)%	196	192	2
International	31	38	(18)%	87	104	(16)
Reportable segment total	321	330		1,049	975	
Corporate and Other ⁽²⁾	(55)	(70)	21	(193)	(238)	19
Total	\$ 266	\$ 260	2 %	\$ 856	\$ 737	16 %
Interest income	2	4		7	21	
Interest expense	(23)	(22)		(66)	(69)	
Loss on divestiture ⁽³⁾	—	(240)		(118)	(240)	
Pension settlement ⁽⁴⁾	—	—		—	(171)	
Cyberattack costs, net of insurance recoveries ⁽⁵⁾	35	(8)		70	(57)	
Streamlined operating model ⁽⁶⁾	—	(10)		—	(13)	
Digital capabilities and productivity enhancements investment ⁽⁷⁾	(26)	(26)		(81)	(85)	
Earnings (losses) before income taxes	\$ 254	\$ (42)	705 %	\$ 668	\$ 123	443 %

⁽¹⁾ Percentages based on rounded numbers.

⁽²⁾ Corporate and Other includes the Better Health VMS business.

⁽³⁾ Represents the loss on divestiture of the Argentina business of \$240 (\$231 after tax) for the three and nine months ended Mar. 31, 2024, and the loss on divestiture of the Better Health VMS business of \$118 for the nine months ended Mar. 31, 2025.

⁽⁴⁾ Represents the pension settlement charge of \$171 (\$130 after tax) for the nine months ended Mar. 31, 2024.

⁽⁵⁾ Represents cyberattack insurance recoveries of \$35 (\$26 after tax) and \$70 (\$53 after tax), respectively, for the three and nine months ended Mar. 31, 2025, and incremental costs of \$8 (\$6 after tax) and \$57 (\$43 after tax), respectively, for the three and nine months ended Mar. 31, 2024.

⁽⁶⁾ Represents restructuring and related costs, net for implementation of the streamlined operating model of \$10 (\$7 after tax) and \$13 (\$10 after tax) for the three and nine months ended Mar. 31, 2024, respectively.

⁽⁷⁾ Represents expenses related to the company's digital capabilities and productivity enhancements investment of \$26 (\$20 after tax) and \$81 (\$62 after tax) for the three and nine months ended Mar. 31, 2025, respectively, and \$26 (\$20 after tax) and \$85 (\$64 after tax) for the three and nine months ended Mar. 31, 2024, respectively.

Condensed Consolidated Balance Sheets

Dollars in millions

	3/31/2025	6/30/2024	3/31/2024
	(Unaudited)		(Unaudited)
ASSETS			
Current assets			
Cash and cash equivalents	\$ 226	\$ 202	\$ 219
Receivables, net	597	695	673
Inventories, net	635	637	674
Prepaid expenses and other current assets	132	88	95
Total current assets	1,590	1,622	1,661
Property, plant and equipment, net	1,245	1,315	1,292
Operating lease right-of-use assets	349	360	379
Goodwill	1,222	1,228	1,229
Trademarks, net	501	538	539
Other intangible assets, net	68	143	149
Other assets	537	545	556
Total assets	\$ 5,512	\$ 5,751	\$ 5,805
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities			
Notes and loans payable	\$ 54	\$ 4	\$ 111
Current operating lease liabilities	85	84	82
Accounts payable and accrued liabilities	2,016	1,486	1,653
Total current liabilities	2,155	1,574	1,846
Long-term debt	2,483	2,481	2,480
Long-term operating lease liabilities	322	334	347
Other liabilities	341	848	853
Deferred income taxes	21	22	24
Total liabilities	5,322	5,259	5,550
Commitments and contingencies			
Stockholders' equity			
Preferred stock	—	—	—
Common stock	131	131	131
Additional paid-in capital	1,304	1,288	1,270
Retained earnings	99	250	34
Treasury stock	(1,331)	(1,186)	(1,189)
Accumulated other comprehensive net (loss) income	(176)	(155)	(155)
Total Clorox stockholders' equity	27	328	91
Noncontrolling interests	163	164	164
Total stockholders' equity	190	492	255
Total liabilities and stockholders' equity	\$ 5,512	\$ 5,751	\$ 5,805